INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion

The company secured a global patent framework covering composition-of-matter and method-of-treatment claims for its lead program, ebstrocel, in epidermolysis bullosa, with protection extending out to 2045. The update strengthens long-dated IP coverage for both the core asset and next-generation engineered modalities, which is supportive for product defensibility and future commercialization optionality.

Analysis

The company secured a global patent framework covering composition-of-matter and method-of-treatment claims for its lead program, ebstrocel, in epidermolysis bullosa, with protection extending out to 2045. The update strengthens long-dated IP coverage for both the core asset and next-generation engineered modalities, which is supportive for product defensibility and future commercialization optionality.